Eisai Inc - Strategic SWOT Analysis Review

Date: February 8, 2017
Pages: 35
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: E6C86BCB691EN
Leaflet:

Download PDF Leaflet

Eisai Inc - Strategic SWOT Analysis Review
Eisai Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.

    Highlights

    Eisai Inc (Eisai) is a healthcare company, which focuses on the discovery, development and marketing of pharmaceutical products. The company's major products include Aricept for Alzheimer’s treatment, Aciphex for acid reflux, Akynzeo for nausea and vomiting dring the course of cancer chemotherapy, Aloxi anti-nausea medication injection, Banzel for adjunctive treatment and Panretin for the treatment of skin lesions in AIDS-related Kaposi's sarcoma. The company’s research and development activities focus on therapeutic areas such as neuroscience; cancer, antibody-based programs; vascular, inflammatory and immunological reaction. Eisai established partnerships and collaborations with global companies such as Pfizer Inc., Janssen Pharmaceutica Inc., and Elan Pharma International Limited and Elan Pharmaceutical Inc for the development and distribution of drugs. The company is a subsidiary of Eisai Co., Ltd. and is headquartered in New Jersey, the US.

    Eisai Inc Key Recent Developments

    Dec 01, 2016: Rebecca Jolley appointed Senior Vice President Americas Commercial, Oncology Business Group at Eisai
    Sep 15, 2016: Eisai Establishes AiM Institute to Discover Human Biology Driven Precision Medicines
    Jun 29, 2016: Eisai Highlights its Strong Pipeline and Innovative Approach to R&D at Company's U.S. Scientific Day
    May 24, 2016: Maria Garrigan appointed Vice President, Global Regulatory Strategy, Oncology Business Group at Eisai
    Apr 20, 2016: Dr. Avinash Desai appointed Vice President, Americas Oncology Medical Affairs, Oncology Business Group at Eisai

    Reasons to Buy
    • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
    • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
    • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
    • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
    Note: Some sections may be missing if data is unavailable for the company.
  • SECTION 1 - ABOUT THE COMPANY

    Eisai Inc - Key Facts
    Eisai Inc - Key Employees
    Eisai Inc - Key Employee Biographies
    Eisai Inc - Major Products and Services
    Eisai Inc - History
    Eisai Inc - Company Statement
    Eisai Inc - Locations And Subsidiaries
    Head Office
    Other Locations & Subsidiaries

    SECTION 2 – COMPANY ANALYSIS

    Eisai Inc - Business Description
    Eisai Inc - Corporate Strategy
    Eisai Inc - SWOT Analysis
    SWOT Analysis - Overview
    Eisai Inc - Strengths
    Eisai Inc - Weaknesses
    Eisai Inc - Opportunities
    Eisai Inc - Threats
    Eisai Inc - Key Competitors

    SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

    Eisai Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
    Eisai Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
    Eisai Inc, Recent Deals Summary

    SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

    Dec 01, 2016: Rebecca Jolley appointed Senior Vice President Americas Commercial, Oncology Business Group at Eisai
    Sep 15, 2016: Eisai Establishes AiM Institute to Discover Human Biology Driven Precision Medicines
    Jun 29, 2016: Eisai Highlights its Strong Pipeline and Innovative Approach to R&D at Company's U.S. Scientific Day
    May 24, 2016: Maria Garrigan appointed Vice President, Global Regulatory Strategy, Oncology Business Group at Eisai
    Apr 20, 2016: Dr. Avinash Desai appointed Vice President, Americas Oncology Medical Affairs, Oncology Business Group at Eisai
    Apr 11, 2016: Beyhan Zaim appointed Vice President Commercial Development & Alzheimer's Disease Global Lead, Neurology Business Group at Eisai
    Apr 06, 2016: Paul Hawthorne appointed Senior Vice President, U.S. Commercial, Neurology Business Group at Eisai
    Mar 30, 2016: Global Drug Maker Eisai Signs Three-Year Contract Extension For CSC’s Total Regulatory Solution as-a-Service
    Feb 16, 2016: Dementia Consortium signs new pharmaceutical partner AbbVie

    SECTION 5 – APPENDIX

    Methodology
    About GlobalData
    Contact Us
    Disclaimer

    LIST OF TABLES

    Eisai Inc, Key Facts
    Eisai Inc, Key Employees
    Eisai Inc, Key Employee Biographies
    Eisai Inc, Major Products and Services
    Eisai Inc, History
    Eisai Inc, Other Locations
    Eisai Inc, Subsidiaries
    Eisai Inc, Key Competitors
    Eisai Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
    Eisai Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
    Eisai Inc, Recent Deals Summary

    LIST OF FIGURES

    Eisai Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
    Eisai Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

    COMPANIES MENTIONED

    White River Health System
    Wellstat Therapeutics Corp
    Salix Pharmaceuticals Ltd
    Research Foundation for Mental Hygiene Inc
    Predictive Biosciences Inc
    Koronis Pharma Inc
    Ceregene Inc
    AstraZeneca Plc
    Adlyfe Inc
    Abraxis BioScience Inc
    Skip to top


    Ask Your Question

    Eisai Inc - Strategic SWOT Analysis Review
    Company name*:
    Contact person*:
    Phone/fax*:
    Email*:
    Request invoice
    Your enquiry:
    Please click on a Check Box below to confirm you are not a robot: